AlzeCure Pharma: AlzeCure is Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

STOCKHOLM, SWEDEN / ACCESSWIRE / February 8, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Related Keywords

Sweden ,United States ,Stockholm ,Swedish ,Alzecure Pharma ,Johan Sandin ,Drug Administration ,Nobel Prize ,Fast Track Designation ,Nasdaq First North Premier Growth Market ,Alzecure ,Dharma ,Moving ,Cowards ,Hase ,Linical ,Trial ,Cd440 ,Ased ,Guiding ,Response ,Rom ,